FAQ

Edivoxetine

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
02420122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor…
OBJECTIVE Three studies examined whether edivoxetine (a highly selective norepinephrine reuptake inhibitor) had efficacy as… (More)
Is this relevant?
2015
2015
A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter…
Inhibition of norepinephrine (NE) reuptake into noradrenergic nerves is a common therapeutic target in the central nervous system… (More)
Is this relevant?
2015
2015
Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.
Norepinephrine, a neurotransmitter in the autonomic sympathetic nervous system, is deaminated by monoamine oxidase to 3,4… (More)
Is this relevant?
2015
2015
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
OBJECTIVE The aim of this analysis was to assess the safety profile of edivoxetine as adjunctive treatment to selective serotonin… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2015
2015
Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
OBJECTIVE When patients with major depressive disorder (MDD) are partial responders to antidepressant therapy, adjunctive… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2014
2014
A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE The purpose of this study was to assess the efficacy and safety of edivoxetine (LY2216684), a selective norepinephrine… (More)
Is this relevant?
2014
2014
A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor…
BACKGROUND This phase 2 study examined the efficacy and tolerability of edivoxetine, a highly selective norepinephrine reuptake… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE The purpose of this study was to assess the clinical outcomes from an open label study of edivoxetine, a selective… (More)
Is this relevant?
2013
2013
The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
To assess the impact of hepatic or renal impairment on the pharmacokinetics (PK) of edivoxetine. Two separate multi-center, open… (More)
  • figure 1
  • figure 4
  • figure 2
  • figure 3
Is this relevant?
2012
2012
Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE Edivoxetine (LY2216684) is a selective and potent norepinephrine reuptake inhibitor (NERI). The pharmacokinetics (PK… (More)
Is this relevant?